NEI Podcast

In this episode, Dr. Andy Cutler is joined by Dr. Jennifer Payne to discuss management of mood disorders influenced by fluctuations in reproductive hormones, particularly in women. They explore medication management during the perinatal period, emphasizing the risks associated with inadequately treated mood disorders. The conversation also addresses strategies for managing hormone-related mood disorders across reproductive stages, including premenstrual dysphoric disorder, premenstrual exacerbation, and perimenopausal depression. Jennifer L. Payne, MD is a psychiatrist specializing in reproductive psychiatry and mood disorders in women. She serves as Vice Chair of Research and Professor in the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia, directing the Reproductive Psychiatry Research Program.  Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.

Join Dr. Andy Cutler and Dr. Cynthia Bulik as they discuss the challenges of diagnosing and treating binge eating disorder (BED). They explore the genetics, neurobiology, and clinical course of BED that inform treatment decisions, and examine how advances in genetic research and emerging pharmacological options may improve outcomes for individuals with BED.  Cynthia Bulik, PhD, FAED is a Distinguished Professor of Eating Disorders in the Department of Psychiatry, a Professor of Nutrition in the Gillings School of Global Public Health and the Founding Director of the Center of Excellence for Eating Disorders at the University of North Carolina at Chapel Hill.    Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.    Resources  Eating Disorders Genetics Initiative (EDGI) 2 - edgi2.org  National Eating Disorders Association - nationaleatingdisorders.org  Families Empowered and Supporting the Treatment of Eating Disorders (FEAST) - feast-ed.org   

Join Dr. Andy Cutler and Dr. Carla Sharp as they discuss the current conceptualization of borderline personality disorder (BPD), including diagnostic challenges, evidence-based treatments, and strategies to reduce stigma by framing BPD as a treatable condition. The conversation also covers recent updates to the APA's BPD guidelines.  Carla Sharp, PhD is a distinguished clinical psychologist specializing in developmental psychopathology, particularly borderline personality disorder (BPD). She is a professor in the Clinical Psychology Doctoral Program and serves as the Associate Dean for Faculty and Research at the University of Houston. Additionally, she directs both the Adolescent Diagnosis, Assessment, Prevention, and Treatment Center and the Developmental Psychopathology Lab at the university.   Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.   

In this CME podcast, Dr. Andrew Cutler and Dr. Roger McIntyre discuss the use of potentially unsafe drug combinations in patients with treatment-resistant psychiatric conditions. They review situations where complex medication regimens may be necessary and how clinicians may proceed in these instances. By addressing these topics, the podcast offers guidance on balancing the potential benefits of combination therapies with the risks associated with polypharmacy in psychiatric care.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Identify common potentially unsafe drug combinations that may be considered in treatment-resistant cases Evaluate the risks and benefits of prescribing potentially unsafe drug combinations for treatment-resistant patients, considering factors such as efficacy, adverse effects, and patient-specific characteristics Develop strategies to monitor and manage patients prescribed potentially unsafe drug combinations Accreditation: In support of improving patient care, this activity has been planned and implemented by HMP Education and Neuroscience Education Institute (NEI). HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with synchronized audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour. Released: March 26, 2025*   Expiration: March 25, 2028 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD25-01 Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ HMP Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse: ANCC contact hours This continuing nursing education activity awards 1.00 contact hour. Provider approved by the California Board of Registered Nursing, Provider #18006 for 1.00 contact hour. Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.00 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI and HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and are unable to report your claimed credit after this 60-day period. Ensure your profile includes your DOB and NABP ID. Physician Associate/Assistant: AAPA Category 1 CME credits HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit. Approval is valid until March 25, 2028. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. This activity awards 1.00 CE Credit. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, HMP Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.00 general continuing education credit. Non-Physician Member of the Healthcare Team: Certificate of Participation HMP Education awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, and cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI and HMP Education take responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, New York Chief Medical Officer, Neuroscience Education Institute, Malvern, Pennsylvania Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, Ontario, Canada CEO, Braxia Scientific Corp, Toronto, ON, Canada Grant/Research: Canadian Institutes of Health Research, China National Natural Research Foundation, Global Alliance for Chronic Diseases, Milken Institute Consultant/Advisor: Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris The remaining Planning Committee members, Content Editors, Peer Reviewer, NEI and HMP planners/staff have no financial relationships to disclose. NEI and HMP Education planners and staff include Gabriela Alarcón, PhD, Ali Holladay, Andrea Zimmerman, EdD, CHCP, Brielle Calleo, and Steven S. Simring, MD, MPH. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported solely by the provider, NEI.

Join Dr. Andy Cutler as he speaks with Dr. Anita Clayton about one of the most common yet least discussed side effects of psychotropic medications—sexual dysfunction. They explore the different aspects of sexual dysfunction that may arise as a side effect, how to distinguish these from symptoms of psychiatric or medical disorders, and how to collaborate with patients to effectively address this challenging issue.  Anita H. Clayton, MD, Wilford W. Spradlin Professor and Chair of Psychiatry & Neurobehavioral Sciences, and Professor of Clinical Obstetrics & Gynecology at the University of Virginia School of Medicine, has focused her research on major depressive disorder, mood disorders associated with reproductive-life events in women (reproductive psychiatry), sexual dysfunction related to illness and medications, and the assessment and treatment of primary sexual disorders.    Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.    Resources  Changes in Sexual Functioning Questionnaire short- form (CSFQ-14)  Validation study for CSFQ-14   

Join Dr. Andy Cutler as he speaks with Dr. Christine Moutier about the unintended effects of the FDA boxed warnings on antidepressant use in pediatric patients—specifically, the underdiagnosis and undertreatment of depression. Their conversation highlights the importance of effectively treating depression to reduce suicide across the lifespan.  Christine Yu Moutier, MD is a leading psychiatrist and the Chief Medical Officer at the American Foundation for Suicide Prevention (AFSP). Since joining AFSP in 2013, Dr. Moutier has led a nationwide movement combining scientific research and grassroots efforts to reduce suicide rates. She has testified before Congress, presented at the White House, and frequently contributes to major media outlets on mental health issues.   Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.    Resources  American Foundation for Suicide Prevention - https://afsp.org/    Save $100 on registration for 2025 NEI Spring Congress with code NEIPOD25  Register today at nei.global/spcongress25f    Never miss an episode!

Join Dr. Andy Cutler as he talks with Dr. Jeffrey Strawn about how clinicians can determine the appropriate scenarios for benzodiazepine deprescribing, best practices for benzodiazepine tapering, and how to balance patient preferences to ensure best outcomes.  Jeffrey R. Strawn, MD is a Professor and Associate Vice Chair of Research in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati (UC) College of Medicine, the Assistant Director of Clinical and Translational Research in the Center for Clinical & Translational Science and Training at UC, and an Associate Professor in the Department of Pediatrics at UC and Cincinnati Children's Hospital Medical Center.   Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Save $100 on registration for 2025 NEI Spring Congress with code NEIPOD25  Register today at nei.global/spcongress25p  Never miss an episode!

In this episode of our special pediatric psychopharmacology series, Dr. Jeffrey Strawn and Dr. Katherine Dahlsgaard review how psychiatric prescribers can incorporate cognitive behavioral therapy (CBT) practices into medication checks with pediatric patients who have anxiety disorders. Specifically, they discuss the importance of using exposures to reduce avoidance behaviors that are characteristic of and feed anxiety disorders. Jeffrey R. Strawn, MD is a Professor and Associate Vice Chair of Research in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati (UC) College of Medicine, the Assistant Director of Clinical and Translational Research in the Center for Clinical & Translational Science and Training at UC, and an Associate Professor in the Department of Pediatrics at UC and Cincinnati Children's Hospital Medical Center. Katherine Dahlsgaard, PhD, ABPP is a licensed clinical psychologist in Philadelphia, Pennsylvania with expertise in CBT for children, adolescents, and adults. Dr. Dahlsgaard specializes in evidence-based assessment and treatment of anxiety and related disorders.   Save $100 on registration for 2025 NEI Spring Congress with code NEIPOD25 Register today at nei.global/spcongress25a   Never miss an episode!

Join Dr. Andy Cutler as he talks with Dr. Descartes Li about the facts and fiction of electroconvulsive therapy (ECT). They discuss the efficacy and potential side effects of ECT, as well as the importance of educating patients and clinicians on ECT in order to overcome stigma associated with this life-saving treatment.   Descartes Li, MD is a psychiatrist who specializes in caring for patients with bipolar disorder and patients receiving electroconvulsive therapy. He directs the UCSF Bipolar Disorders Program and the UCSF Electroconvulsive Therapy Program. Dr. Li's research interests include bipolar disorder, electroconvulsive therapy and medical education.    Resources  University of California, San Francisco ECT FAQ    Save $100 on registration for 2025 NEI Spring Congress with code NEIPOD25  Register today at nei.global/spcongress25f    Never miss an episode!

In this special episode, we present highlights from the PsychopharmaStahlogy Show, hosted by Dr. Andy Cutler and featuring Dr. Stephen Stahl. Join us as we share clips from the most popular episodes of the series, showcasing some of the most though-provoking moments. (01:13) Clip from Treating ADHD Across the Lifespan with Dr. David Goodman (16:16) Clip from Management of Complex Treatment-Resistant Psychotic Disorders with Dr. Michael Cummings (29:31) Clip from Underutilized Psychiatric Drugs: Lithium with Dr. Jonathan Meyer (42:50) Clip from The Antisocial Personality Disorder Spectrum: Diagnosis and Treatment with Dr. James Knoll Save $100 on registration for 2025 NEI Spring Congress with code NEIPOD25 Register today at nei.global/spcongress25f Never miss an episode!

In this episode of our special pediatric psychopharmacology series, Dr. Jeffrey Strawn and Dr. Robyn Thom discuss the situations in which psychotropic medications are appropriate for children with autism spectrum disorder. They also explore strategies for managing side effects of these medications, including cases involving polypharmacy in this population.   Jeffrey R. Strawn, MD is a Professor and Associate Vice Chair of Research in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati (UC) College of Medicine, the Assistant Director of Clinical and Translational Research in the Center for Clinical & Translational Science and Training at UC, and an Associate Professor in the Department of Pediatrics at UC and Cincinnati Children's Hospital Medical Center.  Robyn Thom, MD is an Assistant Professor at Harvard Medical School and a staff psychiatrist at the Massachusetts General Hospital Lurie Center for Autism. Dr. Thom specializes in treating children and adults with autism spectrum disorder and other neurodevelopmental disorders, anxiety disorders, and mood disorders.  Save $100 on registration for 2025 NEI Spring Congress with code NEIPOD25 Register today at https://nei.global/spcongress25p Never miss an episode!

Join Drs. Andy Cutler and Roger McIntyre as they discuss the most significant advancements in psychopharmacology over the past year. Their conversation highlights groundbreaking developments and innovations in the field of psychiatry.  Resources  This Month in Psychopharmacology  Never miss an episode!

In this CME podcast, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the history of muscarinic receptor science in schizophrenia and how that informs the mechanisms of action of novel muscarinic-targeting drugs for this disorder. They also discuss the efficacy and safety of these drugs and provide practical strategies for prescribing xanomeline-trospium.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Discuss the history of muscarinic receptor science and the role of muscarinic receptors in schizophrenia treatment Differentiate novel and in-development muscarinic-targeting treatments for schizophrenia based on their unique mechanisms of action, efficacy, and tolerability data   Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: November 27, 2024*   Expiration: November 26, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-SCHIZ01  Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until November 26, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry and psychopharmacology — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Jonathan M. Meyer, MD Voluntary Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Consultant/Advisor: AbbVie, Alkermes, Bristol Myers Squibb, Intra-Cellular, Neurocrine, Sumitomo, Teva Speakers Bureau: AbbVie, Alkermes, Axsome, Bristol Myers Squibb, Intra-Cellular, Neurocrine, Teva The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Meghan M. Grady, BA, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an educational grant from Bristol Myers Squibb.

In this episode of our special pediatric psychopharmacology series, Dr. Jeffrey Strawn and Dr. Adelaide Robb explore the nuanced use of lithium in treating bipolar disorder among children and adolescents. Their discussion delves into critical aspects of lithium treatment, including carefully calibrated dosing regimens, comprehensive side effect management, and the essential role of parental involvement in treatment decisions.  Jeffrey R. Strawn, MD is a Professor and Associate Vice Chair of Research in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati (UC) College of Medicine, the Assistant Director of Clinical and Translational Research in the Center for Clinical & Translational Science and Training at UC, and an Associate Professor in the Department of Pediatrics at UC and Cincinnati Children's Hospital Medical Center.  Adelaide S. Robb, MD is a psychopharmacologist who specializes in mood disorders, anxiety, and attention deficit disorder. She is Chief of the Division of Psychiatry and Behavioral Sciences at Children's National Hospital in Washington, DC.  Never miss an episode!

This episode includes extended Q&A sessions that address your unanswered questions from the following presentations delivered at the 2024 Congress in Colorado Springs, Colorado:  (00:23) Panic On the Playground! Managing Social Anxiety in Pediatric Patients by Katherine Dahlsgaard, PhD, ABPP and Jeffrey Strawn, MD (Q&A with Dr. Dahlsgaard)   (15:12) Inflammatory Remarks: Our Evolving Understanding of the Role of Inflammation in Mental Health by Roger McIntyre, MD, FRCPC and Vladimir Maletic, MD, MS (Q&A with Dr. McIntyre)   (35:33) Wake Me Up Before You Go-Go: Strategies for Improving Sleep-Wake Issues by Thomas Schwartz, MD   (51:32) Beyond the Blues: Risk, Recognition, and Relief from Perinatal Mood and Anxiety Disorders by Lisa Tremayne, RN, PMH-C, CBC (lisa.tremayne@rwjbh.org)  Never miss an episode!

In this special episode of the NEI Podcast, Dr. Andy Cutler interviews the founder of NEI, Dr. Stephen Stahl about the origins of NEI and the NEI Congress. They also field personal and clinical questions submitted my podcast listeners and NEI members across social media! Tune in for an insightful and fun conversation celebrating 20 years of NEI Congress!  Never miss an episode!

In this CME episode, Drs. Andrew Cutler and Roger McIntyre discuss the challenges and importance of diagnosing bipolar disorder as early as possible in the course of the illness. They also review strategies to achieve a correct diagnosis to provide the most efficacious and tolerable treatments available for bipolar disorder. Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Employ effective screening tools and assessment strategies to enhance diagnostic accuracy and achieve early diagnosis of bipolar disorder Develop patient-centered treatment plans that incorporate current evidence and individual patient factors Utilize shared decision-making approaches to optimize treatment outcomes for patients with bipolar disorder Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: November 01, 2024*   Expiration: October 31, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-BD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 31, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, New York Chief Medical Officer, Neuroscience Education Institute, Malvern, Pennsylvania Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, Ontario, Canada CEO, Braxia Scientific Corp, Toronto, Ontario, Canada Grant/Research: Canadian Institutes of Health Research, China National Natural Research Foundation, Global Alliance for Chronic Diseases, Milken Institute Consultant/Advisor: Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Alkermes, Inc.

In this CME episode, Dr. Andy Cutler interviews Dr. Leslie Citrome about the impact of tardive dyskinesia on patient-reported outcomes and quality of life. They discuss how to correctly assess and diagnose tardive dyskinesia, as well as effective management strategies that incorporate the individual needs of patients.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Understand the physical, psychological, social, and occupational impacts of tardive dyskinesia (TD) on patients Identify clinical tools and patient-reported outcome measures to assess the severity and impact of TD Formulate evidence-based treatment strategies for TD that enhance patient outcomes and quality of life Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: October 23, 2024*   Expiration: October 22, 2027 *NEI maintains a record of participation for six (6) years.   CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-TD   Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 22, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Delpor, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, Medavante-ProPhase, Merck, Mitsubishi-Tanabe Pharma, Neumora, Neurocrine, Neurelis, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumitomo/Sunovion, Supernus, Teva, University of Arizona, Vanda Speakers Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer, Reviva (options) The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Teva Pharmaceuticals.

In the first episode of a special pediatric psychopharmacology series hosted by Dr. Jeffrey Strawn, Dr. John Walkup joins the podcast to discuss deprescribing in pediatric patients. The conversation delves into the situations that warrant deprescribing from antidepressants, selecting the right time to do so, and dealing with relapse, as well as much more!  Jeffrey R. Strawn, MD is a Professor and Associate Vice Chair of Research in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati (UC) College of Medicine, the Assistant Director of Clinical and Translational Research in the Center for Clinical & Translational Science and Training at UC, and an Associate Professor in the Department of Pediatrics at UC and Cincinnati Children's Hospital Medical Center.  John T. Walkup, MD is Head of the Pritzker Department of Psychiatry and Behavioral Health at Ann & Robert H. Lurie Children's Hospital of Chicago and a Margaret C. Osterman Professor of Psychiatry and Behavioral Science. He also serves as Director of the Division of Child and Adolescent Psychiatry in the Department of Psychiatry and Behavioral Sciences at Northwestern University Feinberg School of Medicine.  Never miss an episode!

This Domestic Violence Awareness Month, we're revisiting an important topic: the often overlooked risk of traumatic brain injury (TBI) among victims of intimate partner violence. Our goal is to shed light on this highly vulnerable group that frequently goes unnoticed in discussions about TBI. By reexamining a previous episode released in March 2020, we aim to raise awareness about the significant dangers faced by those experiencing domestic abuse, particularly the risk of brain injuries resulting from physical violence in intimate relationships.  Deb York, MSN, PMHNP-BC, APRN, CCRA is a board certified Psychiatric-Mental Health Nurse Practitioner practicing in Colorado Springs, Colorado. She completed her research certification as a Certified Clinical Research Associate at the Association of Clinical Research Professionals, and is the Director of Clinical Research at Mountain Mind.    Her research focuses on conducting clinical trials to identify and evaluate novel psychopharmacological and neuroradiological interventions for traumatic brain injury, mood disorders, and pediatric psychiatric illnesses. Deb has over 25 years in the clinical trials industry conducting clinical research in pharmaceuticals & biologics, with a specialty in Women's Health, CNS & psychiatric clinical trials.  Never miss an episode!

Join Dr. Andy Cutler as he talks with Dr. Joan Striebel about the syndrome of catatonia, including its dynamic presentation, treating the underlying disorder, and why clinicians must raise their index of suspicion when evaluating symptoms that could indicate catatonia is present.  Dr. Joan Striebel is a psychiatrist at the California Department of State Hospitals, which is the largest forensic mental health hospital system in the nation.    Resources:  Bush-Francis Catatonia Rating Scale Assessment Resources  Catatonia and Its Treatments  Catatonia: A Clinician's Guide to Diagnosis and Treatment  Catatonia: From Psychopathology to Neurobiology  Guidelines for the management of catatonia    Never miss an episode!

In this CME episode, Dr. Andrew Cutler interviews Dr. Charles Vega about the challenges of identifying bipolar disorder in primary care and how to over come them. They also discuss strategies for initiating and managing pharmacological treatment long term in collaboration with patients and psychiatric specialists. Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objective: After completing this educational activity, you should be better able to: Identify the key symptoms and diagnostic criteria for bipolar disorder to accurately screen and diagnose patients presenting in primary care settings Describe strategies for initiating and managing pharmacological treatment of bipolar disorder, including appropriate use of mood stabilizers, antipsychotics, and monitoring for side effects and adherence Explain the role of the primary care provider in coordinating care for bipolar disorder patients, including providing psychoeducation, determining appropriate level of care, and collaborating with mental health specialists when needed Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 45 minutes Released: September 04, 2024*   Expiration: September 03, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-PrimCare Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 0.75 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credits™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 0.75 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 0.75 contact hour (.075 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 0.75 AAPA Category 1 credit. Approval is valid until September 03, 2027. PAs should only claim credit commensurate with the extent of their participation. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Disclosures are from the original live presentation, unless otherwise noted. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NYChief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Charles P. Vega, MD Clinical Professor, School of Medicine, University of California - Irvine, Orange, CA Consultant/Advisor: Boehringer Ingelheim, Exact Sciences The remaining Planning Committee member(s), Content Editor(s), Peer Reviewer(s), and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, Samantha Joy, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported solely by the provider, NEI.

What are the primary barriers to clozapine utilization in the United States, and how do these barriers impact patient care? What are some common misconceptions or negative attitudes among prescribers regarding clozapine, and how can these be addressed? What are some effective strategies for improving the management of clozapine's side effects to encourage its use? What strategies can be implemented to improve education and awareness about clozapine?  Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on underutilized psychotropic drugs.  Today, Dr. Andy Cutler interviews Dr. Jonathan Meyer and Dr. Stephen Stahl about factors that have led to the underutilization of clozapine in psychiatry.  Let's listen to Part 3 of our theme: Underutilized Psychiatric Drugs.  Subscribe to the NEI Podcast, so that you don't miss another episode!  Resources  The Clozapine Handbook   Clozapine titrations paper (see Supplementary Material):   de Leon J et al. Pharmacopsychiatry 2022;55(2):73-86.  FDA committees meeting to discuss reevaluation of the Clozapine REMS program (November 19, 2024): click here. 

Join Dr. Andy Cutler as he talks with the co-author of the winning poster from the 2023 NEI Congress Young Investigator Poster Competition, Dr. Richard Price. They discuss the objectives, design, and key findings of the poster titled, “Improved Mood and Weight Gain Mitigation Following Switch from Aripiprazole to Cariprazine.” They also discuss the potential implications of these findings and applications of cariprazine in psychiatry.  Dr. Richard Price is an Assistant Professor of Clinical Psychiatry at Weill Cornell Medical College. Maxwell Zachary Price, the lead author of the winning poster, is a medical student at Hackensack Meridian School of Medicine.  See the winning poster here.    Learn about upcoming NEI Meetings at https://nei.global/meetings  

What are the main reasons MAOIs are underutilized in psychiatric practice despite their proven efficacy for certain conditions? What are the key dietary restrictions patients must follow when taking MAOIs? What are the critical drug-drug interactions clinicians must be aware of when prescribing MAOIs? What clinical pearls or tips would you give to clinicians looking to become more comfortable using these agents?  Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on underutilized psychotropic drugs.  Today, Dr. Andy Cutler interviews Dr. Thomas Schwartz and Dr. Stephen Stahl about factors that have led to the underutilization of MAOIs in psychiatry.  Let's listen to Part 2 of our theme: Underutilized Psychiatric Drugs.  Subscribe to the NEI Podcast, so that you don't miss another episode!  Resources  Email roundtable@maoiexperts.topicbox.com for guidance on prescribing MAO inhibitors  The Prescriber's Guide to Classic MAO Inhibitors (Phenelzine, Tranylcypromine, Isocarboxazid) for Treatment-Resistant Depression  Practical Guide for Prescribing MAOIs: Debunking Myths and Removing Barriers 

What are the current smoking rates among LGBTQIA+ individuals compared to the general population? What unique barriers do LGBTQIA+ individuals face when trying to quit smoking? What are the recommended pharmacotherapies and behavioral interventions for smoking cessation? What training is needed for providers to deliver culturally affirmative smoking cessation treatment for LGBTQIA+ patients?  Dr. Rhonda Schwindt is an Associate Professor at The George Washington University School of Nursing. She is a nationally certified Psychiatric-Mental Health Nurse Practitioner with an active clinical practice specializing in LGBTQIA+ health, trauma, and treatment-resistant mood disorders. Dr. Schwindt earned a Doctor of Nursing Practice degree from Case Western Reserve University, a Master of Science in Nursing from Indiana University School of Nursing, a Bachelor of Arts from Purdue University, and a diploma in nursing from St. Elizabeth School of Nursing. Dr. Schwindt has a funded program of research focused on improving health outcomes for the LGBTQIA+ community. She led a team of researchers that examined barriers to, and facilitators of, smoking cessation and treatment utilization in the transgender and gender expansive population as well as studies exploring best practices for teaching graduate students how to provide affirming care. Dr. Schwindt has received international recognition as an outstanding graduate nurse educator and for clinical excellence in the care of persons living with serious mental illness.  Resources  Pride in Being Tobacco-Free  UCSF Smoking Cessation Leadership Center  Fenway Health  Trevor Project 

In this CME episode, Dr. Andrew Cutler interviews Dr. Laxman Bahroo about the current landscape of tardive dyskinesia, including screening, diagnosis, and treatment. Practical strategies based on the latest data are reviewed at length, particularly for long-term management of tardive dyskinesia.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Consider the individual patient profile and symptoms when determining a treatment plan for patients with tardive dyskinesia Integrate latest safety, efficacy, and tolerability data of VMAT2 inhibitors into decision-making processes when considering treatment options for tardive dyskinesia Evaluate practical strategies for patient follow-up and long-term VMAT2 inhibitor treatment Evaluate and integrate recent updates and advancements regarding evidence-based treatment strategies for tardive dyskinesia Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit. Estimated Time to Complete: 1 hour Released: June 26, 2024*   Expiration: June 25, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-02-TD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hours Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEUs). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until June 25, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.0 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Laxman B. Bahroo, DO, MS, FAAN Professor and Residency Program Director, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC Consultant/Advisor: AbbVie, Amneal, Ipsen, Kyowa Kirin, Merz, Neurocrine, Revance, Supernus Speakers Bureau: AbbVie, Acadia, Acorda, Amneal, Ipsen, Kyowa Kirin, Merz, Neurocrine, Supernus, Teva The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Meghan Grady, Brielle Calleo, and Andrea Zimmerman, EdD. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences.

What are the properties of lithium that make it a unique treatment option? What are the main reasons why lithium is underutilized in clinical practice, and what are the consequences of underutilization? What are the common myths or misconceptions about lithium's safety and tolerability? How can we better educate patients about the benefits of lithium and address concerns about side effects or monitoring requirements that may impact adherence?  Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on underutilized psychotropic drugs.  Today, Dr. Andy Cutler interviews Dr. Jonathan Meyer and Dr. Stephen Stahl about factors that have led to the underutilization of lithium in psychiatry.  Let's listen to Part 1 of our theme: Underutilized Psychiatric Drugs.  Subscribe to the NEI Podcast, so that you don't miss another episode!    Resource  The Lithium Handbook 

In this CME episode, Dr. Andrew Cutler interviews Desiree Matthews, PMHNP-BC on the importance of engaging patients across all facets of tardive dyskinesia management beginning with screening to symptoms monitoring to treatment. The role of patient experience and preferences in shared decision-making regarding treatment for tardive dyskinesia is discussed at length.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Recognize the significance of comprehensive measures that assess both healthcare practitioner-perceived severity of tardive dyskinesia symptoms and the patient-reported impact of tardive dyskinesia on daily life Engage in informed discussions with patients about the rationale behind incorporating additional medications to manage side effects arising from primary antipsychotic medication Consider all facets of patient health, including physical, mental, and social well-being, when formulating strategies for managing tardive dyskinesia symptoms Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit. Estimated Time to Complete: 1 hour. Released: June 05, 2024*   Expiration: June 04, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-01-TD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.00 ANCC contact hours Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 0.5 continuing education hour(s) of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour(s) (.10 CEUs). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit(s). Approval is valid until June 04, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Desiree M. Matthews, MSN, PMHNP-BC Founder and Clinical Director, Different MHP, PC, Charlotte, NC Consultant/Advisor: Alkermes, Biogen, Boehringer Ingelheim, Karuna, Indivior, Janssen Pharmaceuticals, Neurocrine Biosciences, Sage Therapeutics, Takeda, Teva Speakers Bureau: AbbVie, Axsome, Neurocrine Biosciences, Teva The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Meghan Grady, and Andrea Zimmerman. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences.

How do symptoms of agitation manifest differently in disorders such as bipolar disorder, schizophrenia, and dementia, and what challenges does this pose for assessment? What are the most effective pharmacological treatments for acute agitation in psychiatric patients, and how do you determine the best course of action? How do cultural factors influence the approach to managing agitation in various mental health conditions? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the “untreatable” dimensions of psychopathology. Today, Dr. Andy Cutler interviews Dr. Leslie Citrome and Dr. Stephen Stahl about the clinical difficulties of treating agitation.  Let's listen to Part 3 of our theme: Untreatable Dimensions of Psychopathology.  Subscribe to the NEI Podcast, so that you don't miss another episode!

What are the hypothesized neurobiological mechanisms that support the use of cannabidiol (CBD) as a treatment for opioid use disorder (OUD)? How does CBD influence cue-induced craving in OUD? What are the challenges and opportunities in further exploring the use of CBD as a potential treatment for OUD? Dr. Joji Suzuki is the Director of the Division of Addiction Psychiatry and Director of Addictions Education in the Department of Psychiatry, Brigham and Women's Hospital, and an Assistant Professor of Psychiatry at Harvard Medical School. His areas of clinical and research interests are the assessment and management of substance use disorders and related conditions in general medical settings, motivational interviewing, office-based opioid treatment, implementation of collaborative models of care, and medical education. He is the site director for the Partners Addiction Psychiatry Fellowship, and is involved with teaching medical students, residents, and allied health professionals. He has authored over 30 peer-reviewed manuscripts and book chapters related to addiction psychiatry.

In this episode, Dr. David Goodman addresses your unanswered questions from his presentation, Setting the Mood: Strategies for Diagnosing and Treating ADHD in the Context of Bipolar Disorder, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this episode, Dr. Manpreet Singh addresses your unanswered questions from her joint presentation, Don't Get Mixed Up! Recognizing and Treating Mixed Features Across the Lifespan, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this episode, Dr. Dani Cabral addresses your unanswered questions from her presentation, Memories in the Future: An Update on the Diagnosis and Treatment of Alzheimer's Disease, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this episode, Dr. Sarah Vinson addresses your unanswered questions from her panel presentation, Serious Mental Illness: A Collaborative Approach, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

How does dysfunction in cognition affect overall treatment outcomes for psychiatric disorders? What are the challenges in treating cognitive deficits in psychiatric conditions? What treatments are in development for cognitive dysfunction? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the “untreatable” dimensions of psychopathology. Today, Dr. Andy Cutler interviews Dr. Richard Keefe and Dr. Stephen Stahl about the clinical difficulties of treating cognitive dysfunction.  Let's listen to Part 2 of our theme: Untreatable Dimensions of Psychopathology. Subscribe to the NEI Podcast, so that you don't miss another episode! ***Register today for the 7th annual NEI Synapse, being held April 19th through the 21st in-person in Las Vegas and online via simulcast. Use discount code PODCAST to save $100 on your registration at nei.global/Synapse.

What are some common challenges faced by caregivers of individuals with dementia? What is comprehensive dementia care and how does it improve quality of life of individuals with dementia and their caregivers? What is the GUIDE Model and why is it needed?  Carolyn Clevenger, DNP, RN, GNP-BC, AGPCNP-BC, FAANP, FGSA is a Professor at the Nell Hodgson Woodruff School of Nursing at Emory University. Dr. Clevenger is a nationally recognized educational leader in advanced practice nursing and in geriatrics and gerontology. She is a Past President of the Gerontological Advanced Practice Nurses Association, Fellow of the American Association of Nurse Practitioners (AANP) and the Gerontological Society of America, and contributor to the AANP Certification Program. She is the director of the nurse-led patient centered medical home for people living with dementia, the Integrated Memory Care Clinic (IMCC). IMCC represents an innovative clinical model that provides memory and primary care in a single integrated model for people living with dementia and their care partners.  Resources Alzheimer's Association KAER toolkit ROON   ***Register today for the 7th annual NEI Synapse, being held April 19th through the 21st in-person in Las Vegas and online via simulcast. Use discount code PODCAST to save $100 on your registration at nei.global/Synapse.

What is the role of mindfulness techniques in the treatment of anxiety disorders and how is it evolving? How does mindfulness-based stress reduction compare to pharmacological treatment for anxiety disorders? What are the hypotheses that have been made about why mindfulness-based treatments work for anxiety? Elizabeth Hoge, MD is a Professor and Director of the Anxiety Disorders Research Program in the Department of Psychiatry at Georgetown University School of Medicine. Dr. Hoge completed her psychiatry residency training and research fellowship at the Massachusetts General Hospital in Boston. During her research fellowship, she earned a Masters in Medical Science from the Harvard Medical School-Massachusetts Institute of Technology program in Health Sciences and Technology with a focus on clinical trials. Her research focuses on treatments for anxiety disorders, including medication, psychotherapy and mindfulness, and the examination of biomarkers of anxiety, stress, and trauma. She has over 50 publications in the medical research literature and is on the Scientific Council of the Anxiety and Depression Association of America. ***Register today for the 7th annual NEI Synapse, being held April 19th through the 21st in-person in Las Vegas and online via simulcast. Use discount code PODCAST to save $100 on your registration at nei.global/Synapse.

What are the cultural factors that should be considered when providing mental health care to migrant and refugee populations? What challenges and opportunities exist in providing mental health care to these communities? How can mental health professionals collaborate with other disciplines to create a holistic approach to address the mental health needs of migrant and refugee populations?  Lisa Fortuna, MD, MPH is the Chief of Psychiatry and Neurosciences at the Riverside School of Medicine. She was the Chief of Psychiatry and Vice-Chair at Zuckerberg San Francisco General Hospital/UCSF and Associate Professor of Clinical Psychiatry. She has been an investigator on several National Institutes of Health and foundation-funded studies of Latino and immigrant mental health, integrated care, access to care including a principle investigator of a NIMH funded R01 aimed at optimizing family navigation for addressing child behavioral health in primary care and a Patient Centered Outcome Research Institute (PCORI) funded multi-site large pragmatic trial on the treatment of childhood anxiety comparing face to face vs. digitally delivered CBT in English and Spanish called Kids FACE FEARS. Her areas of expertise are child and adolescent psychiatry, treatment and research on PTSD across the lifespan, immigrant mental health and disparities/ access to care including digital interventions research. 

How does anhedonia impact the overall treatment plan for patients with major depressive disorder and other psychiatric conditions? What are some of the most challenging aspects of treating anhedonia in patients? Are there any new treatments in development that may be helpful for treating anhedonia? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the “untreatable” dimensions of psychopathology. Today, Dr. Andy Cutler interviews Dr. Vladmir Maletic and Dr. Stephen Stahl about the clinical difficulties of treating anhedonia  Let's listen to Part 1 of our theme: Untreatable Dimensions of Psychopathology. Subscribe to the NEI Podcast, so that you don't miss another episode!

During Black History Month, we revisit an enlightening conversation with Dr. Sarah Vinson about the impact of structural racism on Black mental health and how mental healthcare providers can make a difference in the lives of patients by leveraging their privilege and skillsets.  Dr. Sarah Y. Vinson is a physician who is triple-board certified in adult, child & adolescent, and forensic psychiatry. She is the founder of the Lorio Psych Group, an Atlanta, GA based mental health practice providing expert care and consultation. Dr. Vinson is also the founder of Lorio Forensics, which provide consultation on a wide variety of cases in criminal, civil, and family court cases. After graduating from medical school at the University of Florida with Research Honors and as an Inductee in the Chapman Humanism Honors Society, she completed her general psychiatry training at Cambridge Health Alliance/Harvard Medical School. While there, she also received specialized training in trauma through the Victims of Violence Program. She then returned to the South to complete fellowships in both child & adolescent and forensic psychiatry at Emory University School of Medicine. In addition to providing mental health care services such as psychotherapy, consultation, and psychopharmacology through her private practice, Dr. Vinson is a Professor and Chair of the Department of Psychiatry & Behavioral Sciences at Morehouse School of Medicine. She is also Adjunct Faculty at Emory University School of Medicine. She is the Past President of the Georgia Council on Child and Adolescent Psychiatry, and the Treasurer of the Georgia Psychiatric Physicians Association. Additionally, she is an Advisor for the Judges Psychiatry Leadership Initiative. Dr. Vinson has been a speaker at national conferences including the American Psychiatric Association Annual Meeting, the American Academy of Child and Adolescent Psychiatry Annual Meeting and The National Urban League Annual Meeting. Dr. Vinson has received numerous awards in recognition of her service and leadership including the University of Florida College of Medicine Outstanding Young Alumna Award and the APA Jeanne Spurlock Minority Fellowship Alumna Achievement Award.    Resources  Social (In)justice in Mental Health  Judges and Psychiatrists Leadership Initiative  Ourselves Black 

Can the therapeutic benefits of psilocybin be achieved without a psychedelic trip? What is the role of psychological support in the therapeutic effect of psilocybin? What is microdosing and what are its potential benefits and risks? What is the path to FDA approval and commercialization of psilocybin and other psychedelics?  Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the role of psychedelics in modern psychiatry.  Today, Dr. Andy Cutler interviews Dr. Charles Raison and Dr. Stephen Stahl about the importance of the psychedelic trip for the therapeutic benefits of psilocybin.  Let's listen to Part 4 of our theme: Classic Psychedelics for the Modern Psychopharmacologist.  Subscribe to the NEI Podcast, so that you don't miss another episode! 

The climate crisis has a wide-reaching impact that negatively affects both acute and long-lasting mental health outcomes. Are there specific populations that are more vulnerable to mental health issues related to the climate crisis? What is the role of mental health professional to combat the negative influence of climate change on mental health? Robin Cooper, MD, is a psychiatrist who has had a private practice in San Francisco for 40 years, is Associate Clinical Professor in the Department of Psychiatry and Behavioral Sciences at the UCSF Medical School, where she is actively involved in efforts to address climate change impacts on mental health and health. She is co-founder of Climate Psychiatry Alliance, a national group of psychiatrists and mental health professionals dedicated to understanding, educating, and advocating about the specific impact of climate change on mental health. As she moves into semi-retirement in her clinical work, her work around climate change impacts on health and mental health have become a second career.

In this CME episode, Dr. Andrew Cutler interviews Dr. Dani Cabral about current and novel diagnostic tools and treatments for Alzheimer's disease. Optional CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CE credit, click nei.global/POD23-MDD Learning Objectives: After completing this educational activity, you should be better able to: Describe the potential role of multimodal imaging and biomarker strategies in the diagnostic process for Alzheimer's disease Assess the safety and efficacy of novel disease-modifying pharmacological treatments for Alzheimer's disease Describe potential future advancements in the diagnosis and treatment of Alzheimer's disease Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewee Dani Cabral, MD Assistant Clinical Professor, Departments of Neurology and of Psychiatry, University of Arizona College of Medicine, Phoenix, AZ Dementia Specialist, Banner Sun Health Research Institute, Sun City, AZ Consultant/Advisor: Eisai, Lilly, Roche/Genentech Interview Questions Author Caroline L. O'Brien, MS Assistant Manager, Grant Development, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewers have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Eisai. Released: December 27, 2023      CE credit expires: December 27, 2026

What do the clinical trials of psilocybin and other psychedelics show in terms of efficacy and safety? How much of the benefit with psychedelic treatment is attributable to psychological support? Is the psychedelic trip important for the therapeutic benefits of psychedelic treatments? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the role of psychedelics in modern psychiatry. Today, Dr. Andy Cutler interviews Dr. Scott Aaronson and Dr. Stephen Stahl about the potential indications and therapeutic benefits of psilocybin and other psychedelics. Let's listen to Part 3 of our theme: Classic Psychedelics for the Modern Psychopharmacologist. Subscribe to the NEI Podcast, so that you don't miss another episode!

In this CME episode, Dr. Andrew Cutler interviews Dr. Jeffrey Strawn about the role of pharmacogenomic testing in guiding treatment of major depressive disorder (MDD). They discuss how pharmacogenomic testing works, the impact of failed treatments and side effects on patients with MDD, and the clinical applications and future directions of pharmacogenomic testing. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-GEN Learning Objectives: After completing this educational activity, you should be better able to: Recognize the role of a patient's genetics in informing the efficacy and tolerability of antidepressants Consider opportunities to use pharmacogenomics as an evidence-based tool that can be employed to inform clinical decision making Implement pharmacogenomic testing to optimize patient outcomes, including symptom improvement, medication response, and remission rate Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewee Jeffrey R. Strawn, MD Professor, Department of Psychiatry and Behavioral Neuroscience and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH Grant/Research: Allergan/AbbVie Consultant/Advisor: Cerevel, Intra-Cellular, Otsuka Pre-Interview Author Gabriela Alarcón, PhD Senior Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Myriad Genetics. Released: December 13, 2023      CME/CE credit expires: December 13, 2026

What were some new treatments approved by the FDA? What did we learn about the long-term safety of methylphenidate in childhood ADHD? Are there benefits to long-term maintenance treatment with antidepressants in bipolar disorder? What did we learn about the safety and efficacy of subcutaneous racemic ketamine for treatment-resistant depression and MDMA for PTSD? In this episode, Dr. Andrew Cutler and Dr. Roger McIntyre address these questions and so much more about this past year in psychopharmacology.   Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function, and medical comorbidity. His work broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.    

In this CME episode, Dr. Andrew Cutler interviews Dr. Vladimir Maletic about the impact of residual symptoms on patients with major depressive disorder, as well as treatment modifications to address residual symptoms in these individuals. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-MDD Learning Objectives: After completing this educational activity, you should be better able to: Describe the burden of residual symptoms in patients with major depressive disorder (MDD) Implement measurement-based care to assess residual MDD symptoms Modify treatment strategies to address residual MDD symptoms, including cognitive impairment, anhedonia, emotional blunting, and sexual dysfunction Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewee Vladimir Maletic, MD, MS Clinical Professor, Department of Psychiatry and Behavioral Science, University of South Carolina School of Medicine Greenville, SC Consultant/ Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Biogen/Sage, Boehringer Ingelheim, Cervel, Intra-Cellular, Janssen, Jazz, Lundbeck, Neurelis, Neumora, Noven, Otsuka, Pax Medica, Relmada, Sunovion, Supernus, Takeda Speakers Bureau: AbbVie, Alfasigma, Alkermes, Axsome, Corium, Intracellular, Janssen, Lundbeck, Otsuka, Sunovion, Supernus, Takeda Pre-Interview Author Caroline L. O'Brien, MS Assistant Manager, Grant Development, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Takeda. Released: November 29, 2023      CME/CE credit expires: November 29, 2026

In this episode, Dr. Vladimir Maletic addresses your unanswered questions from his presentations, “From Despair to Delight: Advances in the Diagnosis and Treatment of Anhedonia” and “Ho Hum to Aha! Treating Anhedonia and Emotional Blunting.”

In this episode, Dr. Leslie Citrome addresses your unanswered questions from his presentation, There's No Place Like Home: Addressing Agitation in Dementia.

What is the role of the 5HT2A receptor in the therapeutic actions of psychedelics? What additional mechanisms may be involved in the therapeutic benefits of classic psychedelics? Is the psychedelic trip necessary for the therapeutic benefit of psychedelics?  Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the role of psychedelics in modern psychiatry.  Today, Dr. Andy Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl about the current understanding of the neurobiological mechanisms underlying the therapeutic benefits of psychedelics.  Let's listen to Part 2 of our theme: Classic Psychedelics for the Modern Psychopharmacologist.  Subscribe to the NEI Podcast, so that you don't miss another episode!